Zai Lab Limited Is Well Positioned For Long-Term Growth
Source: SeekingAlpha
2025-05-28 02:48:06 ET
Summary
- Zai Lab leverages partnerships and regulatory expertise to commercialize innovative drugs in China, reducing trial risks and accelerating market entry.
- A robust pipeline with multiple anticipated product launches each year, driving strong revenue growth toward a $1.5–$2 billion target by 2028.
- The company’s strong balance sheet and diverse product portfolio minimize risk.
- ZLAB’s global ambitions and commercialization expertise make it a compelling long-term buy.
- Valuation target: ~$7.5 billion market cap in 2028 representing a 23% CAGR.
...
Read the full article on Seeking Alpha
For further details see:
Zai Lab Limited Is Well Positioned For Long-Term Growth
Zai Lab Limited
NASDAQ: ZLAB
ZLAB Trading
-2.15% G/L:
$18.67 Last:
179,805 Volume:
$18.86 Open:
ZLAB Latest News
February 26, 2026 07:00:00 am
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
ZLAB Stock Data
$2,174,273,322
105,108,310
0.9%
39
N/A
Biotechnology & Life Sciences
Healthcare
CN
Shanghai
